Australia markets close in 6 hours 4 minutes
  • ALL ORDS

    7,209.00
    -72.10 (-0.99%)
     
  • ASX 200

    6,982.70
    -62.20 (-0.88%)
     
  • AUD/USD

    0.7722
    -0.0008 (-0.11%)
     
  • OIL

    63.83
    +0.01 (+0.02%)
     
  • GOLD

    1,825.50
    +1.50 (+0.08%)
     
  • BTC-AUD

    64,725.63
    +2,192.83 (+3.51%)
     
  • CMC Crypto 200

    1,361.48
    -26.42 (-1.90%)
     
  • AUD/EUR

    0.6392
    -0.0002 (-0.03%)
     
  • AUD/NZD

    1.0754
    +0.0002 (+0.02%)
     
  • NZX 50

    12,483.02
    +54.90 (+0.44%)
     
  • NASDAQ

    13,109.15
    +107.51 (+0.83%)
     
  • FTSE

    6,963.33
    -41.30 (-0.59%)
     
  • Dow Jones

    34,021.45
    +433.79 (+1.29%)
     
  • DAX

    15,199.68
    +49.46 (+0.33%)
     
  • Hang Seng

    27,718.67
    -512.37 (-1.81%)
     
  • NIKKEI 225

    27,448.01
    0.00 (0.00%)
     

Vir Biotechnology to Provide Corporate Update and Report First Quarter 2021 Financial Results on May 6, 2021

  • Oops!
    Something went wrong.
    Please try again later.
Vir Biotechnology, Inc.
·1-min read
  • Oops!
    Something went wrong.
    Please try again later.

SAN FRANCISCO, April 22, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the first quarter ended March 31, 2021 on Thursday, May 6, 2021.

The update will be provided via a press release after market close and will be accessible under Press Releases in the Investors section of the Vir website at www.vir.bio.

About Vir Biotechnology
Vir Biotechnology is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting COVID-19, hepatitis B virus, influenza A and human immunodeficiency virus. For more information, please visit www.vir.bio.

Contact:
Cara Miller
VP, Corporate Communications
cmiller@vir.bio
+1 415 941 6746